19 January 2021 - The Scottish Medicines Consortium has given a green light to Roche’s Rozlytrek for a rare form of lung cancer, almost seven months after NICE backed the drug in England.

Rozlytrek (entrectinib) can now be used by the NHS in Scotland as a treatment option for ROS1 positive, advanced non-small cell lung cancer not previously treated with ROS1 inhibitors.

Read Pharmaphorum article